Search Results
Sep 01, 2026, 08:00 ET QC Ware and IonQ Demonstrate High-Precision Hybrid Quantum Workflow for Drug Discovery
electrostatic interaction energy, a major factor in how tightly a drug candidate binds to its target, at complex metal centers such as the iron site in P450nor, could improve candidate ranking and help identify metabolic risks earlier in the drug-discovery process."Running the same hybrid workflow on
More news about: QC Ware Corp.
Sep 01, 2026, 08:00 ET DISA Global Solutions Expands Compliance Capabilities with Acquisition of TEAM Companies
TEAM and DISA serve many of the same industries and share a commitment to helping employers maintain safe, compliant workplaces.In addition to drug testing, background screening, occupational health, and training services, TEAM provides contractor compliance monitoring through Alert, its proprietary
More news about: DISA Global Solutions
Sep 01, 2026, 08:00 ET Andelyn Biosciences to Scale Manufacturing for Genprex's Diabetes Gene Therapy Program
manufacturing. Manufacturing activities are expected to include process optimization, scale-up, analytical qualification, potency assay development, and drug product manufacturing in a cGMP-compliant facility.In Type 1 diabetes, Genprex's candidate is designed to transform pancreatic alpha cells into
More news about: Andelyn Biosciences
Sep 01, 2026, 08:00 ET Pyrotech Therapeutics Doses First Subject in Phase 1 Study of PTT-121, the World's First Selective GSDMD Inhibitor to Enter Clinical Development
long been regarded as the holy grail of pyroptosis drug development — a target of extraordinary therapeutic potential that defied conventional medicinal chemistry approaches. By achieving this milestone, we are not only validating our proprietary drug discovery platform but also opening an entirely new
More news about: Pyrotech Therapeutics
Sep 01, 2026, 08:00 ET Kalohexis Appoints Garry Menzel, Ph.D., to Board of Directors
regulator of metabolic homeostasis, to help people live healthier lives. Kalohexis' therapeutic peptide candidates are designed to safely and effectively drug central melanocortin-3 and -4 receptors (MC3R/MC4R) to treat many metabolic disorders. Kalohexis' lead pipeline programs are 710GO, an oral dual MC3R/MC4R agonist
More news about: Kalohexis
Sep 01, 2026, 07:30 ET Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy
nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S. Food and Drug Administration (FDA) in February 2018, and Fast Track Designation (FTD) for glioblastoma in August 2020. Paxalisib was also
More news about: Kazia Therapeutics Limited
Sep 01, 2026, 07:15 ET Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer
nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S. Food and Drug Administration (FDA) in February 2018, and Fast Track Designation (FTD) for glioblastoma in August 2020. Paxalisib was also
More news about: Kazia Therapeutics Limited
Sep 01, 2026, 07:00 ET Xentria Advances XTMAB-16 Clinical Development in Pulmonary Sarcoidosis Following FDA Feedback
and help slow granuloma formation. Through dedicated regulatory work and focus from Xentria's team, XTMAB-16 was granted Orphan Drug Designation by the FDA for the New Drug Entity in November 2020. A Phase 1 clinical trial in healthy volunteers was completed in 2022. No TNFα inhibitor is currently approved
More news about: Xentria, Inc.
Sep 01, 2026, 07:00 ET 94% of U.S. Adults Concerned About the Frequency of Food Recalls, New GS1 US Survey Shows
effort."Regulation aimed at strengthening recall effectiveness and improving food safety will go into effect on July 20, 2028. The U.S. Food and Drug Administration's (U.S. FDA's) Food Safety Modernization Act (FSMA) Section 204 Food Traceability Rule is designed to improve traceability for high-risk
More news about: GS1 US
Sep 01, 2026, 07:00 ET RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®
recurrent C. diff infection (rCDI). FDA-approved in 2022 and Health Canada-approved in 2025, Rebyota, was granted a Breakthrough Therapy and received Orphan Drug designations and generated approximately $16.9 million in 2025 U.S. net salesProprietary Clenpiq, a ready-to-use (no mixing
More news about: RedHill Biopharma Ltd.
Sep 01, 2026, 06:30 ET Highlandia Soars to Best in Show, Leads Four-Medal Sweep at 2026 Summer PR%F Awards as Brand Launches Two New THC Elixirs
pets. Do not drive or operate machinery after consumption. Do not use if pregnant, nursing or subject to drug testing. Statements in this press release have not been evaluated by the U.S. Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.Contact
More news about: Lifted Made
Sep 01, 2026, 06:30 ET Immunic Appoints Chitrang Davé as Chief Data and Digital Officer
from late-stage clinical development to commercial readiness. In this role, he will support the preparation of the data package for the potential New Drug Application (NDA) submission and commercialization of vidofludimus calcium (IMU-838) in multiple sclerosis (MS)."We are continuing to add to
More news about: Immunic, Inc.
Sep 01, 2026, 06:00 ET Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference
ingredients, or API products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. More information and resources are available at www.amphastar.com.Amphastar's
More news about: Amphastar Pharmaceuticals, Inc.
Sep 01, 2026, 06:00 ET IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences
committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop
More news about: IDEAYA Biosciences, Inc.
Sep 01, 2026, 05:30 ET Exonate Becomes Foventa Therapeutics
Phase Ib/IIa clinical studies, and a Phase IIb study in NPDR is in preparation, with a design validated through a Type C meeting with the US Food and Drug Administration.For more information, visit Foventa.com
More news about: Foventa Therapeutics
Sep 01, 2026, 01:39 ET Cherubic Ventures Closes $68.88 Million Fund VI as AUM Surpasses $500 Million
include AI-powered patent technology platform Patlytics, along with healthcare and drug development companies Max AI,
More news about: Cherubic Ventures
Sep 01, 2026, 01:25 ET Canada's Drug Agency issues final positive recommendation supporting public reimbursement of Leqembi®
treatment of early Alzheimer's disease. In November 2025, a new drug application for subcutaneous formulation of Leqembi for initiation treatment was submitted in Japan. In December 2025, Leqembi was included in the "Commercial Insurance Innovative Drug List", recently introduced by the National Healthcare Security
More news about: BioArctic
Sep 01, 2026, 01:21 ET Canada's Drug Agency issues final positive recommendation supporting public reimbursement of Leqembi®
treatment of early Alzheimer's disease. In November 2025, a new drug application for subcutaneous formulation of Leqembi for initiation treatment was submitted in Japan. In December 2025, Leqembi was included in the "Commercial Insurance Innovative Drug List", recently introduced by the National Healthcare Security
More news about: BioArctic
Sep 01, 2026, 00:01 ET North Carolina Approves Reimbursement of VR Therapy for Neurodivergent Residents Under NC Innovations Waiver
waiver reimbursement for Floreo's services, including Tennessee, New York, and Wisconsin.As the first VR autism technology to receive the Food and Drug Administration's (FDA) breakthrough device designation, Floreo is backed by a growing body of research conducted with world-renowned programs like the
More news about: Floreo
Aug 31, 2026, 23:50 ET Orexo reaches non-binding agreement in principle to settle investigation by US Department of Justice
treatments for severe diseases and life-saving rescue medications to meet future healthcare needs. At the core of our innovation is AmorphOX®, a proprietary drug delivery technology that improves bioavailability and stability for both large and small molecules, enabling new approaches to administration, manufacturing,
More news about: Orexo
Aug 31, 2026, 23:41 ET Orexo reaches non-binding agreement in principle to settle investigation by US Department of Justice
treatments for severe diseases and life-saving rescue medications to meet future healthcare needs. At the core of our innovation is AmorphOX®, a proprietary drug delivery technology that improves bioavailability and stability for both large and small molecules, enabling new approaches to administration, manufacturing,
More news about: Orexo
Aug 31, 2026, 19:53 ET Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
action.What is this about: On February 13, 2026, the U.S. Food and Drug Administration ("FDA") issued a Complete Response Letter ("CRL") to Disc Medicine regarding its bitopertin program. The FDA stated they could not approve Disc Medicine's new drug application ("NDA") as there were uncertainties in the NDA
More news about: THE ROSEN LAW FIRM, P. A.
Aug 31, 2026, 17:58 ET Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering
nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S. Food and Drug Administration (FDA) in February 2018, and Fast Track Designation (FTD) for glioblastoma in August 2020. Paxalisib was also
More news about: Kazia Therapeutics Limited
Aug 31, 2026, 17:53 ET ActivatedYou's Essential Skin Food Wins Collagen Product of the Year at the 2026 Mindful Awards
YouTube.*All individuals are unique. Your results can and will vary.†These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.Press Contact: Laura
More news about: ActivatedYou
Aug 31, 2026, 17:01 ET Beverly Hills MD Launches Sheer Radiance SPF Drops: A Mineral-Based SPF 50 Serum That Fights Dark Spots, Uneven Tone, and Fine Lines
cover the face and neck evenly. Apply at least 15 minutes before sun exposure, and reapply every 2 hours, especially after sweating or swimming. See the Drug Facts panel for complete directions and warnings.Will Sheer Radiance SPF Drops leave a white cast? Definitely not. This SPF serum is specifically
More news about: Beverly Hills MD